How is the Mereo Biopharma Group Plc - ADR today?

The Mereo Biopharma Group Plc - ADR today is trading in the down by -2.71% at 2.15.

How has Mereo Biopharma Group Plc - ADR performed historically?

The Mereo Biopharma Group Plc - ADR is currently trading down -2.71% on an intraday basis in the past week the index fell -4.02%. The index has been down -10.42% in the past quarter and fell -37.68% in the past year. You can view this in the overview section.

What is Mereo Biopharma Group Plc - ADR Annual Net Profit?

Mereo Biopharma Group Plc - ADR Annual Net Profit fell 46.79% in the last year to $43.25 M. Its sector's average net profit growth for the last fiscal year was -11.09%.

What is Mereo Biopharma Group Plc - ADR Price to Earning Ratio?

Mereo Biopharma Group Plc - ADR Price to Earning Ratio is -7.24, which is negative.

What is Mereo Biopharma Group Plc - ADR Stock Price?

Mereo Biopharma Group Plc - ADR Stock Price fell 37.68% and underperformed its sector by 93.15% in the past year.

What is Mereo Biopharma Group Plc - ADR Quarterly Net profit?

Mereo Biopharma Group Plc - ADR Quarterly Net profit fell 43.97% YoY to $12.89 M. Its sector's average net profit growth YoY for the quarter was -212.88%.

What is Mereo Biopharma Group Plc - ADR Debt to Equity Ratio?

Mereo Biopharma Group Plc - ADR Debt to Equity Ratio of 0.11 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Mereo Biopharma Group Plc - ADR Return on Equity(ROE)?

Mereo Biopharma Group Plc - ADR Return on Equity(ROE) for the last financial year was -77.58%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Mereo Biopharma Group Plc - ADR Mutual Fund Holding?

Mereo Biopharma Group Plc - ADR Mutual Fund Holding increased by 3.01% in the last quarter to 5.08.

What is Mereo Biopharma Group Plc - ADR Interest Coverage Ratio?

Mereo Biopharma Group Plc - ADR Interest Coverage Ratio is -30.57, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

What is Mereo Biopharma Group Plc - ADR Institutional Holding?

Mereo Biopharma Group Plc - ADR Institutional Holding decreased by 1.53% in the last quarter to 68.57.

Mereo Biopharma Group Plc - ADR XNAS: MREO

Mereo Biopharma Group Plc - ADR Live Share Price Today, Share Analysis and Chart

Name: Mereo Biopharma Group Plc - ADR: Is Infosys Ltd. worth buying?
Item: Mereo Biopharma Group Plc - ADR
Rating: 0.74125
Author: Trendlyne DVM scores

about

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disea...

2.15 -0.06 (-2.71%)

57.17% Fall from 52W High

623.4K XNAS Volume

XNAS 30 May, 2025 5:30 PM (EDT)

Board Meeting

The next board meeting for Mereo Biopharma Group Plc - ADR is on 04 Jun 2025 for the purpose of Jefferies Global Healthcare Conference 2025 See details

Not Eligible

Expensive Valuation

3.5 / 100

Technically Bearish

26.2 / 100

1Yr Price target upside is 250%

8 analysts

Mereo Biopharma Group Plc ... Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Mereo Biopharma Group Plc - ADR Live Share Price Today, Share Analysis and Chart

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disea...

57.17% Fall from 52W High

SWOT Analysis

Mereo Biopharma Group Plc ... Live Price Chart

Mereo Biopharma Group Plc - ADR FAQ

How is Mereo Biopharma Group Plc - ADR today?

Mereo Biopharma Group Plc - ADR today is trading in the red, and is down by -2.71% at 2.15.

How has Mereo Biopharma Group Plc - ADR performed historically?

Mereo Biopharma Group Plc - ADR is currently trading down -2.71% on an intraday basis. In the past week the stock fell -4.02%. stock has been down -10.42% in the past quarter and fell -37.68% in the past year. You can view this in the overview section.